Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Comparability of Two PF-07940367 Formulations in Healthy Participants
NCT06190561Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of osivelotor in sickle cell disease (SCD) (2 arms), sponsored by Pfizer. Primary endpoint: Area under the whole blood concentration versus time curve from time zero to 336 hours. Started Jan 2024; status: completed.
02
Drugs
osivelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06190561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190561.